DE60129712D1 - Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten - Google Patents

Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten

Info

Publication number
DE60129712D1
DE60129712D1 DE60129712T DE60129712T DE60129712D1 DE 60129712 D1 DE60129712 D1 DE 60129712D1 DE 60129712 T DE60129712 T DE 60129712T DE 60129712 T DE60129712 T DE 60129712T DE 60129712 D1 DE60129712 D1 DE 60129712D1
Authority
DE
Germany
Prior art keywords
alkyl
haloalkyl
unsubstituted
oxazolylaryloxyacetic
acid derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60129712T
Other languages
English (en)
Other versions
DE60129712T2 (de
Inventor
Dawn Alisa Brooks
Scott Eugene Connor
Samuel James Dominianni
Alexander Glenn Godfrey
Lann Stacy Gossett
Christopher John Rito
Allie Edward Tripp
Alan M Warshawsky
Leonard Larry Winneroski
Guoxin Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE60129712D1 publication Critical patent/DE60129712D1/de
Application granted granted Critical
Publication of DE60129712T2 publication Critical patent/DE60129712T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
DE60129712T 2000-08-23 2001-08-23 Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten Expired - Lifetime DE60129712T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22723300P 2000-08-23 2000-08-23
US227233P 2000-08-23
PCT/US2001/022615 WO2002018355A1 (en) 2000-08-23 2001-08-23 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists

Publications (2)

Publication Number Publication Date
DE60129712D1 true DE60129712D1 (de) 2007-09-13
DE60129712T2 DE60129712T2 (de) 2008-07-03

Family

ID=22852305

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60129712T Expired - Lifetime DE60129712T2 (de) 2000-08-23 2001-08-23 Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten

Country Status (9)

Country Link
US (3) US6982278B2 (de)
EP (1) EP1313715B1 (de)
JP (1) JP2004509084A (de)
AT (1) ATE368653T1 (de)
AU (1) AU2001284658A1 (de)
CA (1) CA2420178A1 (de)
DE (1) DE60129712T2 (de)
ES (1) ES2288982T3 (de)
WO (1) WO2002018355A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03001558A (es) 2000-08-23 2003-06-06 Lilly Co Eli Agonistas del receptor activado del proliferador de peroxisoma.
ATE368653T1 (de) * 2000-08-23 2007-08-15 Lilly Co Eli Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
WO2002016332A1 (en) 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
US7105551B2 (en) 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
HUP0400268A2 (hu) * 2001-06-07 2004-07-28 Eli Lilly And Co. Peroxiszóma proliferátorral aktivált receptorokat (PPAR) módosító hatóanyagok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
US20110065129A1 (en) 2001-07-27 2011-03-17 Lowe Derek B Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
AR036237A1 (es) 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
ITRM20020014A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del
WO2003072102A1 (en) 2002-02-25 2003-09-04 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
WO2003072100A1 (en) * 2002-02-25 2003-09-04 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
UA79755C2 (en) * 2002-04-16 2007-07-25 Bayer Pharmaceuticals Corp Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
WO2004011446A1 (en) * 2002-07-26 2004-02-05 Bayer Pharmaceuticals Corporation Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
US7129268B2 (en) * 2002-10-28 2006-10-31 Novo Nordisk A/S Peroxisome proliferator activated receptor-active arylene acetic acid derivatives
AU2003276234B2 (en) * 2002-11-08 2007-04-19 F. Hoffmann-La Roche Ag Substituted 4-alkoxyoxazol derivatives as PPAR agonists
US7192970B2 (en) * 2002-11-26 2007-03-20 Chipscreen Biosciences, Ltd. Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity
BRPI0407180A (pt) 2003-02-14 2006-02-07 Lilly Co Eli Composto, composição farmacêutica, métodos para modular um receptor ativado pelo proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição, para diminuir a glicose no sangue em um mamìfero, para tratar ou prevenir diabetes mellitus, doença cardiovascular e sìndrome x em um mamìfero, e, uso de um composto
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
JP4754487B2 (ja) * 2003-08-20 2011-08-24 エミスフィアー テクノロジーズ インコーポレイテッド グルカゴン様ペプチド（ｇｌｐ）−１化合物またはメラノコルチン４受容体（ｍｃ４）アゴニストペプチドの経口デリバリーのための化合物、方法および製剤
EP1658273B1 (de) * 2003-08-20 2007-01-03 Eli Lilly And Company Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4-rezeptor (mc4) als agonist wirkenden peptids
CN1875002B (zh) * 2003-11-05 2011-08-03 霍夫曼-拉罗奇有限公司 作为ppar激动剂的苯基衍生物
JP2007509998A (ja) * 2003-11-05 2007-04-19 エフ．ホフマン−ラ　ロシュ　アーゲー Ｐｐａｒ活性化剤としてのベンズ環付加された化合物
ATE515494T1 (de) * 2004-05-05 2011-07-15 High Point Pharmaceuticals Llc Neue verbindungen, deren herstellung und verwendung
WO2005105735A1 (en) * 2004-05-05 2005-11-10 Novo Nordisk A/S Phenoxyacetic acid derivatives as ppar agonists
JP2007284352A (ja) * 2004-08-05 2007-11-01 Dai Ichi Seiyaku Co Ltd ピラゾール誘導体
WO2006108491A1 (en) * 2005-04-11 2006-10-19 Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg Improved process for preparing oxazole nitriles
EP2386540A1 (de) 2005-12-22 2011-11-16 High Point Pharmaceuticals, LLC Neue Verbindungen, ihre Herstellung und Verwendung
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
TW201000107A (en) * 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118155A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
CN102834401B (zh) * 2010-02-03 2016-08-24 无限药品股份有限公司 脂肪酸酰胺水解酶抑制剂
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
CN104230836B (zh) * 2014-09-29 2016-08-31 中国科学院成都生物研究所 苯基噁唑类化合物及在制备治疗癌症的药中的应用
US11078528B2 (en) 2015-10-12 2021-08-03 Advanced Cell Diagnostics, Inc. In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto
CA3185909A1 (en) 2020-07-22 2022-01-27 Reneo Pharmaceuticals, Inc. Crystalline ppar-delta agonist
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
JPH08325250A (ja) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規置換フェノール誘導体
ES2202582T3 (es) 1996-02-02 2004-04-01 MERCK & CO., INC. Agentes antidiabeticos.
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
CZ53699A3 (cs) 1996-08-19 1999-07-14 Japan Tobacco Inc. Deriváty propionové kyseliny a jejich použití
KR100620337B1 (ko) 1998-03-10 2006-09-13 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제
US6121300A (en) * 1998-11-10 2000-09-19 Wagle; Dilip R. Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts
AU7073400A (en) * 1999-08-27 2001-03-26 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
JP4316787B2 (ja) * 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
ATE368653T1 (de) * 2000-08-23 2007-08-15 Lilly Co Eli Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
WO2002016332A1 (en) 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
MXPA03001558A (es) * 2000-08-23 2003-06-06 Lilly Co Eli Agonistas del receptor activado del proliferador de peroxisoma.

Also Published As

Publication number Publication date
WO2002018355A1 (en) 2002-03-07
US20080146631A1 (en) 2008-06-19
EP1313715B1 (de) 2007-08-01
EP1313715A1 (de) 2003-05-28
DE60129712T2 (de) 2008-07-03
US20050250825A1 (en) 2005-11-10
US20040024034A1 (en) 2004-02-05
CA2420178A1 (en) 2002-03-07
ES2288982T3 (es) 2008-02-01
US7351728B2 (en) 2008-04-01
JP2004509084A (ja) 2004-03-25
AU2001284658A1 (en) 2002-03-13
ATE368653T1 (de) 2007-08-15
US6982278B2 (en) 2006-01-03

Similar Documents

Publication Publication Date Title
DE60129712D1 (de) Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
CY1107679T1 (el) Παραγωγα οξαζολυλ-αρυλ προπιονικου οξεος και χρηση αυτων σαν αγωνιστες ppar
PE20000625A1 (es) Derivados de acido oxiiminoalcanoico
NO20053762L (no) Kondensert furanforbindelse.
DE69725113D1 (de) Azetidin- und Pyrrolidinderivate
DK1178982T3 (da) Heterocykliske, substituerede aminoazacykliske forbindelser, der er nyttige som midler til centralnervesystemet
DK1008592T3 (da) Cykliske amidderivater, som inhiberer cathepsin K
DE69327944T2 (de) Thiazolidindione-Derivate, ihre Herstellung und Verwendung
ATE173256T1 (de) Azolidindion-derivate und ihre anwendung als antihyperglykämika
ATE466861T1 (de) Aminderivate
DE69509452D1 (de) Tetrazolinon-Herbizide
NO20072753L (no) 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer
WO2003048130A3 (en) Peroxisome proliferator activated receptor agonists
NO307087B1 (no) 3-(hetero)arylkarboksylsyrederivater, midler inneholdende dem, anvendelse av dem og mellomprodukter i deres fremstilling
WO2007068815A3 (fr) Derives heterocycliques, leur preparation et leur application en therapeutique.
EA200200470A1 (ru) Новые производные тиазолидиндиона в качестве противодиабетических средств
MXPA02003952A (es) Derivados de imidazol como inhibidores de la fosfodieterasa vii.
ATE235450T1 (de) 2-indanmethanolderivate und ihre verwendung als riechstoffe
EP1211253A4 (de) Trizyklische dihydrobenzofurane, verfahren zu deren herstellung und mittel
BR0207966A (pt) Composição farmacêutica contendo derivados 1,3-tiazina
CY1110613T1 (el) Υποκατεστημενες θειαζολες και η χρησιμοποιηση τους για την παρασκευη φαρμακων
PE20050221A1 (es) Derivados de 3-(benzoilureido)-tiofeno sustituidos y procedimiento para su preparacion
CA2258960A1 (en) A process for preparing naphthyridones and intermediates
DE60333095D1 (de) Imidazolverbindungen und ihre verwendung als alpha-2 adrenorezeptorliganden

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336